Neurizon Therapeutics Beheer

Beheer criteriumcontroles 1/4

De CEO Neurizon Therapeutics is Michael Thurn, benoemd in May2024, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 415.11K, bestaande uit 69.4% salaris en 30.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.58% van de aandelen van het bedrijf, ter waarde € 334.50K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.5 jaar en 0.5 jaar.

Belangrijke informatie

Michael Thurn

Algemeen directeur

AU$415.1k

Totale compensatie

Percentage CEO-salaris	69.4%
Dienstverband CEO	less than a year
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Michael Thurn's beloning veranderd ten opzichte van Neurizon Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$415k	AU$288k	-AU$9m

Compensatie versus markt: De totale vergoeding ($USD 269.76K ) Michael } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 471.14K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Michael te vergelijken met de prestaties van het bedrijf.

CEO

Michael Thurn

less than a year

Tenure

AU$415,107

Compensatie

Dr. Michael Thurn, Ph D., serves as Managing Director, CEO and Director of PharmAust Limit since May 31, 2024. He was Chief Executive Officer of Neurizon Therapeutics Limited (formerly known as PharmAust L...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Thurn	MD, CEO & Director	less than a year	AU$415.11k	0.58% € 334.5k
John Clark	Chief Operating Officer	less than a year	AU$153.58k	0.13% € 74.1k
Nicky Wallis	Chief Scientific Officer	less than a year	AU$26.16k	geen gegevens
Fiona Milner	General Manager of Epichem Pty Ltd	2.4yrs	AU$26.69k	geen gegevens
Gary Pitt	Head of Chemistry	no data	geen gegevens	geen gegevens
James Rixson	Head of Production	no data	geen gegevens	geen gegevens
Herbert Brinkman	Head of Manufacturing	less than a year	geen gegevens	geen gegevens
Stefan Ross	Company Secretary	less than a year	geen gegevens	geen gegevens

0.5yrs

Gemiddelde duur

Ervaren management: Het managementteam van ECQ0 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Thurn	MD, CEO & Director	less than a year	AU$415.11k	0.58% € 334.5k
Kathryn MacFarlane	Director	less than a year	AU$3.13k	0.054% € 31.2k
Christian Schirvel	Veterinary Clinical Advisory Board Member	7.1yrs	geen gegevens	geen gegevens
Angela Frimberger	Veterinary Clinical Advisory Board Chair	7.1yrs	geen gegevens	geen gegevens
Barbara Kitchell	Veterinary Advisory Board Member	6.9yrs	geen gegevens	geen gegevens
Marcus Hughes	Director	less than a year	AU$10.80k	2.97% € 1.7m
Sergio Duchini	Non-Executive Chairman	less than a year	AU$9.38k	0.27% € 156.0k

0.5yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van ECQ0 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.5 jaar), wat duidt op een nieuw bestuur.

Neurizon Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

PharmAust Limited, Annual General Meeting, Sep 30, 2024

PharmAust Limited, Annual General Meeting, Nov 20, 2023

PharmAust Limited Announces Executive Changes

PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023

No independent directors

PharmAust Limited, Annual General Meeting, Nov 10, 2022

Recent updates

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

PharmAust Limited, Annual General Meeting, Sep 30, 2024

PharmAust Limited has filed a Follow-on Equity Offering.

PharmAust Limited has completed a Follow-on Equity Offering in the amount of AUD 3.459 million.

PharmAust Limited has announced a Derivatives Offering in the amount of AUD 39.612456 million.

PharmAust Limited, Annual General Meeting, Nov 20, 2023

Full year 2023 earnings released: AU$0.019 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

PharmAust Limited Announces Executive Changes

PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023

First half 2023 earnings released: EPS: AU$0 (vs AU$0.004 loss in 1H 2022)

PharmAust Limited Progresses to Elevated Doses in MND Patients

PharmAust Limited Completes First Cohort of Six Patients in Its Phase 1/2 Clinical Trial of Lead Drug Candidate Monepantel in Motor Neurone Disease/Amyotrophic Lateral Sclerosis

PharmAust Limited Announces MND Trial Completes Enrolment of First Patient Cohort

No independent directors

PharmAust Limited, Annual General Meeting, Nov 10, 2022

PharmAust Limited Recruits First Pet Dog with B Cell Lymphoma in US Canine Phase 2 Trial Assessing the Efficacy of Monepantel Treatment

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.004 loss in FY 2021)

Pharmaust Updates on Canine Cancer Trials

PharmAust Limited Announces Resignation of Richard Mollard as Chief Scientific Officer

Pharmaust Limited Announces Arrival of Mpl Tablets in Melbourne for Motor Neuron Disease Clinical Trial

PharmAust Limited Expands Lymphoma Canine Trial to the USA

No independent directors

PharmAust Limited Announces Preliminary MPL Anti-Viral Leukaemia Preclinical WEHI Results

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

First half 2022 earnings: Revenues and EPS in line with analyst expectations

PharmAust Limited Provides Update on Manufacture of MPL & Tablets for Clinical Trials

Full year 2021 earnings released: AU$0.004 loss per share (vs AU$0.005 loss in FY 2020)

Pharmaust Limited Achieves Phase IIB Dog Trial's Interim Clinical Endpoints

PharmAust Receives Ethics Approval for Phase I Trial of Monepantel in Motor Neurone Disease

PharmAust Limited Announces Phase IIb Canine Trial Identifies Therapeutic Window for MPL

PharmAust Ltd Provides an Update on Phase IIb Trial Testing the Effects of Monepantel Upon Pet Owners' Dogs with Treatment Naïve B Cell Lymphoma

PharmAust Limited Announces Monepantel COVID-19 Testing in the Netherlands

PharmAust and Leiden University Medical Centre Provide Update on Monepantel COVID-19 Testing

PharmAust and Olivia Newton-John Cancer Research Institute to Continue MPL Pre-clinical Investigations

PharmAust Ltd to Commence Phase IIb Dog Cancer Trial

PharmAust Limited Provides an Update on Analysis at the Olivia Newton-John Cancer Research Institute Investigating the Mechanism of Action of Monepantel Upon Cancer Cells

Pharmaust Ltd, Entered into A Service Agreement with Leiden University Medical Center (Lumc) in Netherlands for Lumc to Test

Full year earnings released - €0.0046 loss per share

Full year earnings released - €0.0046 loss per share

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur